Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
2 findings from 1 review
Quality of life: change in CFQoL score from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Eradication of P aeruginosa from the respiratory tract: number of participants eradicated after three month treatment phase · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in eradication of P aeruginosa from the respiratory tract: number of… compared with TNS plus oral placebo (low certainty).
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
FVC (% predicted) Change from baseline · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
no estimate extracted
18 participants
Low
Change in weight (kg) · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).
1 finding from 1 review
Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
Number experiencing adverse effects · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in adverse effects of antibiotics: number of participants experiencing… compared with TNS plus oral placebo (moderate certainty).
1 finding from 1 review
Inhaled steroid dose · mild asthma
1 finding from 1 review
Mean dose of inhaled corticosteroids per person per day (BUD equivalent mcg/day) · people with asthma
1 finding from 1 review
Number of participants achieving complete inhaled steroid withdrawal 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid may leads to higher number of participants achieving complete inhaled steroid withdrawal… compared with placebo + steroid (steroid reduction) (low certainty).
1 finding from 1 review
>50% reduction in inhaled steroid usage 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to higher >50% reduction in inhaled steroid usage 28 to 32 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
1 finding from 1 review
Exacerbations requiring a course of oral or inhaled corticosteroids or emergency department visits · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in exacerbations (number of people experiencing ≥ 1 exacerbations) compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review